New York, May 20, 2026, 13:02 (EDT)
- Neuphoria Therapeutics was last up 23 cents to $5.00, a gain of about 4.8%, at 12:35 p.m. EDT in regular Nasdaq action.
- Biotech ETFs climbed as well. The SPDR S&P Biotech ETF added 3.7%, while the iShares Nasdaq Biotechnology ETF gained 1.8%.
- No license revenue came in for the March quarter, according to a May 15 quarterly filing. The company posted a net loss of $505,063 and reported $19.4 million in cash as of March 31.
Neuphoria Therapeutics Inc. shares traded higher in midday action Wednesday. The move came as biotech stocks attracted buyers, although Neuphoria’s newest filing pointed to a focus on conserving cash and weighing options over any immediate drug revenue.
The stock, which trades on Nasdaq, last changed hands at $5.00, up 23 cents. Shares opened at $4.71 and ranged from $4.77 to $5.00. Volume hit 33,745 shares on the latest trade—enough to stand out, though well below large-cap levels.
Neuphoria isn’t trading on clinical momentum anymore. Shares are now moving based on cash, deal potential and what’s left in the pipeline since the company ended the social anxiety disorder program.
Neuphoria reported in its 10-Q it did not record any license revenue for the quarter to March 31. That’s down from $15 million for the same period last year. The company turned in a net loss of $505,063, or 9 cents a share. Last year’s quarter was net income of $11.3 million, or $6.55 a share.
Neuphoria reported $19.4 million in cash and cash equivalents as of March 31, with working capital at $20.1 million, according to the filing. Management thinks recent cost-cutting moves should give enough operating cash to last past the fourth quarter of fiscal 2027. The company defined cash runway as how long it can keep running before it needs to raise more money.
October’s failure of AFFIRM-1, a Phase 3 trial for BNC210 in social anxiety disorder, sets the stage here. Phase 3 trials are usually late-stage tests aimed at gaining approval. At the time, the company said the study did not hit its main endpoint, the trial’s key measure, and said it planned a strategic review—looking at things like mergers, deals, partnerships or changes to its portfolio.
Neuphoria CEO Spyros Papapetropoulos said in October the company would try to “conserve our cash position” and look at “all options” after missing in the trial. The company later disclosed in a filing it had let go all but one employee, ended leases and stopped or cut R&D, as it looks for a merger or other deal. Neuphoria Therapeutics Inc.
Biotech stocks moved up. The SPDR S&P Biotech ETF climbed 3.7%. The iShares Nasdaq Biotechnology ETF added 1.8%. Compass Pathways traded up 6.6%, and GH Research was up 1.8% too. NEUP shares had a stronger session as a result, despite no new press release from the company.
But cash could turn negative for Neuphoria too. The company hasn’t posted product revenue or hit profitability, and it warned it will need much more cash to develop, test and commercialize its pipeline. If a deal or partner doesn’t surface, investors may look harder at how fast the company is burning cash, its liabilities, and whether new share sales could dilute them.
The stock’s latest move doesn’t seem tied to fresh clinical results. It looks more like small-cap biotech trading—liquidity, a firmer sector, and hopes for the strategic review to land a better option than just winding down. A real update, not Wednesday’s pop, will probably matter more.
